136 related articles for article (PubMed ID: 33811533)
1. Lack of expression of LMO2 clone SP51 identifies MYC rearrangements in aggressive large B-cell lymphomas.
Vazquez I; Papaleo N; Lop J; Puiggros A; Sanchez-Gonzalez B; Diez-Feijoo R; Gimeno E; Andrade-Campos M; Salar A; Espinet B; Salido M; Tapia G; Carreras J; Ferrer A; Arenillas L; Calvo X; Colomo L
Virchows Arch; 2021 Dec; 479(6):1073-1078. PubMed ID: 33811533
[TBL] [Abstract][Full Text] [Related]
2. LMO2-negative Expression Predicts the Presence of MYC Translocations in Aggressive B-Cell Lymphomas.
Colomo L; Vazquez I; Papaleo N; Espinet B; Ferrer A; Franco C; Comerma L; Hernandez S; Calvo X; Salar A; Climent F; Mate JL; Forcada P; Mozos A; Nonell L; Martinez A; Carrio A; Costa D; Dlouhy I; Salaverria I; Martin-Subero JI; Lopez-Guillermo A; Valera A; Campo E;
Am J Surg Pathol; 2017 Jul; 41(7):877-886. PubMed ID: 28288039
[TBL] [Abstract][Full Text] [Related]
3. Role of immunohistochemistry in the era of genetic testing in MYC-positive aggressive B-cell lymphomas: a study of 209 cases.
Agarwal R; Lade S; Liew D; Rogers TM; Byrne D; Feleppa F; Juneja S; Westerman DA
J Clin Pathol; 2016 Mar; 69(3):266-70. PubMed ID: 26307073
[TBL] [Abstract][Full Text] [Related]
4. Nodal diffuse large B-cell lymphomas in children and adolescents: immunohistochemical expression patterns and c-MYC translocation in relation to clinical outcome.
Gualco G; Weiss LM; Harrington WJ; Bacchi CE
Am J Surg Pathol; 2009 Dec; 33(12):1815-22. PubMed ID: 19816150
[TBL] [Abstract][Full Text] [Related]
5. Clinical Interest of LMO2 Testing for the Diagnosis of Aggressive Large B-Cell Lymphomas.
Vazquez I; Papaleo N; Garcia E; Salido M; Salar A; Hernandez S; Calvo X; Colomo L
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32260556
[TBL] [Abstract][Full Text] [Related]
6. Definition of MYC genetic heteroclonality in diffuse large B-cell lymphoma with 8q24 rearrangement and its impact on protein expression.
Valera A; Epistolio S; Colomo L; Riva A; Balagué O; Dlouhy I; Tzankov A; Bühler M; Haralambieva E; Campo E; Soldini D; Mazzucchelli L; Martin V
Mod Pathol; 2016 Aug; 29(8):844-53. PubMed ID: 27125356
[TBL] [Abstract][Full Text] [Related]
7. Round-robin testing for LMO2 and MYC as immunohistochemical markers to screen MYC rearrangements in aggressive large B-cell lymphoma.
Papaleo N; Climent F; Tapia G; Luizaga L; Azcarate J; Bosch-Schips J; Muñoz-Marmol AM; Salido M; Lome-Maldonado C; Vazquez I; Colomo L
Virchows Arch; 2023 Jun; ():. PubMed ID: 37368083
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Myocyte Enhancer Factor 2B Versus Other Germinal Center-associated Antigens in the Differential Diagnosis of B-Cell Non-Hodgkin Lymphomas.
Moore EM; Swerdlow SH; Gibson SE
Am J Surg Pathol; 2018 Mar; 42(3):342-350. PubMed ID: 29309299
[TBL] [Abstract][Full Text] [Related]
9. A combination of LMO2 negative and CD38 positive is useful for the diagnosis of Burkitt lymphoma.
Liu Y; Bian T; Zhang Y; Zheng Y; Zhang J; Zhou X; Xie J
Diagn Pathol; 2019 Sep; 14(1):100. PubMed ID: 31484540
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
[TBL] [Abstract][Full Text] [Related]
11. Mutational Landscape of TdT+ Large B-cell Lymphomas Supports Their Distinction From B-lymphoblastic Neoplasms: A Multiparameter Study of a Rare and Aggressive Entity.
Bhavsar S; Liu YC; Gibson SE; Moore EM; Swerdlow SH
Am J Surg Pathol; 2022 Jan; 46(1):71-82. PubMed ID: 34392269
[TBL] [Abstract][Full Text] [Related]
12. Detection of MYC rearrangement in high grade B cell lymphomas: correlation of MYC immunohistochemistry and FISH analysis.
Lynnhtun K; Renthawa J; Varikatt W
Pathology; 2014 Apr; 46(3):211-5. PubMed ID: 24614699
[TBL] [Abstract][Full Text] [Related]
13. [Aggressive B-cell lymphomas of gastrointestinal tract: a clinicopathologic analysis of 54 cases].
Zhou J; Xia C; Shen Q; Yin H; Zhang X; Shi Q; Zhou X; Ma J
Zhonghua Bing Li Xue Za Zhi; 2014 Jan; 43(1):8-14. PubMed ID: 24713242
[TBL] [Abstract][Full Text] [Related]
14. High expression of LMO2 in Hodgkin, Burkitt and germinal center diffuse large B cell lymphomas.
Shams TM
J Egypt Natl Canc Inst; 2011 Dec; 23(4):147-53. PubMed ID: 22776842
[TBL] [Abstract][Full Text] [Related]
15. C-MYC overexpression predicts aggressive transformation and a poor outcome in mucosa-associated lymphoid tissue lymphomas.
Huang W; Guo L; Liu H; Zheng B; Ying J; Lv N
Int J Clin Exp Pathol; 2014; 7(9):5634-44. PubMed ID: 25337204
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of HGAL and LMO2 immunohistochemistry in the identification of follicular lymphomas of the non-gastric gastrointestinal tract.
Chapman-Fredricks J; Younes SF; Fan YS; Sandoval-Sus JD; Natkunam Y; Lossos IS
Appl Immunohistochem Mol Morphol; 2013 May; 21(3):200-4. PubMed ID: 22914613
[TBL] [Abstract][Full Text] [Related]
17. Low LIM-domain only 2 (LMO2) expression in aggressive B cell lymphoma correlates with
Chapman J; Verdun RE; Lossos IS
Leuk Lymphoma; 2021 Oct; 62(10):2547-2550. PubMed ID: 33988072
[No Abstract] [Full Text] [Related]
18. MYC cytogenetic status correlates with expression and has prognostic significance in patients with MYC/BCL2 protein double-positive diffuse large B-cell lymphoma.
Wang XJ; Medeiros LJ; Lin P; Yin CC; Hu S; Thompson MA; Li S
Am J Surg Pathol; 2015 Sep; 39(9):1250-8. PubMed ID: 25828389
[TBL] [Abstract][Full Text] [Related]
19. BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome.
Tibiletti MG; Martin V; Bernasconi B; Del Curto B; Pecciarini L; Uccella S; Pruneri G; Ponzoni M; Mazzucchelli L; Martinelli G; Ferreri AJ; Pinotti G; Assanelli A; Scandurra M; Doglioni C; Zucca E; Capella C; Bertoni F
Hum Pathol; 2009 May; 40(5):645-52. PubMed ID: 19144384
[TBL] [Abstract][Full Text] [Related]
20. LIM domain only 2 protein expression, LMO2 germline genetic variation, and overall survival in diffuse large B-cell lymphoma in the pre-rituximab era.
Cerhan JR; Natkunam Y; Morton LM; Maurer MJ; Asmann Y; Habermann TM; Vasef MA; Cozen W; Lynch CF; Allmer C; Slager SL; Lossos IS; Chanock SJ; Rothman N; Hartge P; Dogan A; Wang SS
Leuk Lymphoma; 2012 Jun; 53(6):1105-12. PubMed ID: 22066713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
